Shots:

• The P-II (CALDOSE-1) trial evaluates IMU-838 9 (DHODH inhibitor) in 263 patients with UC at 78 study sites including Ukraine & Poland. The results are expected in June 2022
• The therapy reduced pro-inflammatory immune cell responses, reduced pro-inflammatory cytokine secretion & T cell proliferation, synergistic effect with anti-TNF Abs in a mixed lymphocyte reaction assay
• The therapy also showed a biological selectivity by targeting hyperactive cells for a normal immune response against pathogens & vaccines for IBD. In the baseline mayo stool frequency scores & mayo rectal bleeding scores i.e., score of 3 for 59% & 10 of patients, score of 2 for 36% & 54% & score of 1 for 5% & 31%

 Ref: Immunic | Image: Linkedin